IDSA Guidelines for Management of COVID-19 (2020)

The Infectious Diseases Society of America (IDSA) has formed a multidisciplinary guideline panel to provide treatment recommendations for coronavirus disease 2019 (COVID-19).^[1]

The panel's current recommendations (subject to change given the rapid evolution of the COVID-19 pandemic) are as follows:

Hydroxychloroquine/chloroquine: In hospitalized patients with COVID-19, the panel recommends hydroxychloroquine/chloroquine in the context of a clinical trial.
Hydroxychloroquine/chloroquine plus azithromycin: In hospitalized patients with COVID-19, the panel recommends hydroxychloroquine/chloroquine plus azithromycin only in the context of a clinical trial.
Combination of lopinavir/ritonavir: In hospitalized patients with COVID-19, the panel recommends the combination of lopinavir/ritonavir only in the context of a clinical trial.
Corticosteroids: In hospitalized patients with COVID-19 pneumonia, the panel suggests against the use of corticosteroids.
Corticosteroids: In hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19, the panel recommends the use of corticosteroids in the context of a clinical trial.
Tocilizumab: In hospitalized patients with COVID-19, the panel recommends tocilizumab only in the context of a clinical trial.
Convalescent plasma: In hospitalized patients with COVID-19, the panel recommends COVID-19 convalescent plasma in the context of a clinical trial.

In addition to these recommendations, the IDSA panel emphasized the overarching goal that patients be recruited into clinical trials to evaluate the efficacy and safety of potential therapies. Such data will help clinicians obtain further benefit-risk information.

The IDSA plans to update these guidelines often; the most recent version is accessible at https://www.idsociety.org/covid19guidelines.

For more information, please go to Coronavirus Disease 2019 (COVID-19).

For more Clinical Practice Guidelines, please go to Guidelines.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: IDSA Guidelines for Management of COVID-19 (2020) - Medscape - Apr 29, 2020.

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

My Alerts